Date Announced: 30 Jun 2016
Second onfocal laser endomicroscopy platform order by from largest hospital purchasing group.
Paris, France and Cambridge, MA, USA, June 30, 2016 - Mauna Kea Technologies (Euronext : MKEA, FR0010609263, OTCQX: MKEAY), inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, announced that is has received today a second order for a Cellvizio endomicroscopy system from Union des Groupements d'Achat Public (UGAP), France's largest hospital purchasing group.
This order is for the University Hospital of Rouen and follows UGAP's initial Cellvizio system purchase for the Avignon Hospital Center, which occurred in late March shortly after Mauna Kea won the "Innovations" competitive bidding launched by UGAP in November 2015.
"We are pleased to see good momentum in France thanks to our partnership with UGAP, with a second Cellvizio order placed this year We continue to work hard in order for French patients to be able to benefit from the same care opportunities than American patients, in spite of French public authorities' failure to address the issue. The Rouen University Hospital is well known for its excellence in the treatment of GI diseases, and its patients will now further benefit from Cellvizio which may save both patients and the healthcare system from costly and potentially morbid repeat procedures" declared Sacha Loiseau, Ph.D., Co-Founder and CEO of Mauna Kea Technologies.
Source: Mauna Kea Technologies
E-mail: via web site
Web Site: www.maunakeatech.com
|© 2023 SPIE Europe||